Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML
Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML
Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL
Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia
PARP inhibitors in prostate cancer: A promise delivered
Targeting a KRAS neoantigen peptide vaccine to DNGR-1 dendritic cells
OncoAlert and ecancer weekly roundup for November 15 - 21, 2020
Clinical genomic testing in prostate cancer
PARP inhibitors for prostate cancer - Nurse's view
Predictors of efficacy in patients with HR positive/HER2 negative ABC: Subgroup analyses of PALOMA-3
OncoAlert and ecancer weekly roundup for November 8 - 14, 2020
Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor